TTK Healthcare Limited (TTKHLTCARE) AI Stock Analysis

• Market Cap: ₹11.57B
• Dividend Yield: 0.95%
• Average Volume (3M): 82.00
• Price to Earnings (P/E): 34.8
• Beta (1Y): 0.79
• Revenue Growth: 6.98%
• EPS Growth: -17.11%
• Country: IN
• Employees: 1,316
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 7.45
• Shares Outstanding: 14,130,333
• 10 Day Avg. Volume: 50
• 30 Day Avg. Volume: 82
• PEG Ratio: 0.68
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 1.91
• P/FCF Ratio: -99.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: ₹905.00 ▼(-12.05% Downside)
• Action: Upgraded Date: 10/29/25
• Date: Action: Upgraded 10/29/25

TTK Healthcare Limited's overall stock score is driven by its strong financial stability and moderate technical indicators. While the company shows solid revenue growth and a healthy balance sheet, cash flow management issues and a fair valuation limit the score. The absence of recent earnings call insights and notable corporate events means these factors did not influence the score.

Positive Factors

Strong balance sheet

Low leverage and a strong equity base give TTK Healthcare durable financial flexibility. A conservatively financed balance sheet supports steady capex, funding for product development and M&A, and resilience to industry shocks, improving long-term survivability and strategic optionality.

Diversified product portfolio

TTK's mix of branded formulations, consumer healthcare, condoms and medical devices spreads revenue across retail, institutional and distribution channels. This structural diversification reduces dependence on any single market cycle and supports more predictable long-term revenue streams.

Robust gross profit margin

A strong gross margin indicates durable pricing power or advantaged cost structure in core products. Sustained gross profitability underpins the ability to invest in brands, salesforce and product quality, providing a buffer against competitive price pressure and supporting long-term cash generation.

Negative Factors

Negative operating cash flow

Persistent negative operating and free cash flow indicate a gap between reported profits and cash conversion. Over months this can restrict reinvestment, slow new product rollouts, force higher working capital financing, and reduce resilience to demand shocks unless cash conversion improves.

Declining EBITDA margin

A falling EBITDA margin signals rising operating costs or margin pressure that can erode operating leverage. If persistent, margin deterioration will reduce internal funding for growth and weaken competitive positioning unless offset by productivity gains or higher-margin product mix shifts.

Negative EPS growth

A ~28% decline in EPS reflects weaker profitability or one-offs that impact shareholder returns. Sustained EPS contraction undermines reinvestment capacity and may constrain compensation and R&D budgets, pressuring long-term growth prospects unless earnings recover.

TTK Healthcare Limited Business Overview & Revenue Model

Company Description

TTK Healthcare Limited engages in the animal welfare and human pharma product, consumer product, medical device, protective device, and food businesses in India and internationally. Its Animal Welfare segment deals in various therapeutic formulations and feed supplements for veterinary use. The company's Consumer Products segment is involved in the marketing and distribution of Woodward's Gripewater, EVA range of cosmetics, Good Home range of scrubbers, air fresheners, etc. its Medical Devices segment manufactures and distributes artificial heart valves; and develops orthopedic implants and instruments. The company's Protective Devices segment manufactures and markets male contraceptives and other allied products. Its Foods segment engages in the manufacturing and marketing of food products, including potato and cereal based pellets. The company's Others segment prints and publishes maps and atlases. Its Human Pharma segment deals in herbal and allopathic formulations for human use. The company was incorporated in 1958 and is headquartered in Chennai, India. TTK Healthcare Limited is a subsidiary of TT Krishnamachari & Co., Ltd.

How the Company Makes Money

TTK Healthcare makes money primarily by selling products across its healthcare and consumer segments. Key revenue streams include: (1) Branded pharmaceuticals/formulations: revenue earned from the sale of prescription and other pharmaceutical products to wholesalers, distributors, pharmacies, and healthcare providers, typically supported by a field sales force and brand marketing. (2) Consumer healthcare and personal protection products (including condoms): revenue generated through the sale of branded consumer products via retail distribution networks, modern trade, and other consumer channels; earnings are driven by volumes, brand positioning, and promotional activity. (3) Medical devices: revenue from manufacturing and selling medical devices (and related supplies) to hospitals, clinics, and other institutional buyers, as well as through distributors; device sales can be influenced by tender/contract wins and hospital procurement cycles. (4) Exports and contract/third-party manufacturing (if applicable within reported segments): revenue may also come from exporting products to international markets and/or manufacturing for other brand owners, where realized income depends on order volumes and negotiated pricing. The company’s earnings are supported by its product portfolio mix, distribution reach, institutional relationships (for devices), and brand-led demand (for consumer categories). Specific segment-wise revenue shares, named partnerships, or customer concentration details are null because they are not available in the provided prompt.

TTK Healthcare Limited Financial Statement Overview

Summary

TTK Healthcare Limited exhibits solid financial performance with strong revenue growth and financial stability. The company has a robust balance sheet with low leverage and high equity ratio. However, challenges in cash flow management, such as negative free cash flow and operating cash flow, need to be addressed.

Income Statement

TTK Healthcare Limited has demonstrated a strong revenue growth trajectory, with a notable increase in total revenue from 2024 to 2025. The gross profit margin is robust, showcasing effective cost management. However, the declining EBITDA margin suggests potential increases in operational costs or inefficiencies.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio and a strong equity ratio, indicating financial stability and low leverage. The high ROE reflects efficient use of equity to generate profits.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow and operating cash flow figures. Although there is an improvement in free cash flow growth year-on-year, the negative operating cash flow to net income ratio highlights ongoing cash management issues.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.25B	8.73B	7.48B	7.25B	5.99B	4.76B
Gross Profit	5.48B	5.04B	4.07B	3.77B	3.09B	1.38B
EBITDA	1.01B	1.06B	999.35M	796.81M	406.58M	373.52M
Net Income	662.66M	816.57M	628.42M	6.40B	415.88M	464.41M
Balance Sheet
Total Assets	12.96B	12.81B	12.01B	11.70B	5.59B	4.94B
Cash, Cash Equivalents and Short-Term Investments	6.01B	8.55B	8.45B	8.47B	2.73B	2.27B
Total Debt	285.86M	242.19M	228.11M	273.29M	222.13M	191.44M
Total Liabilities	2.10B	2.16B	2.00B	2.17B	2.29B	2.00B
Stockholders Equity	10.85B	10.65B	10.01B	9.53B	3.30B	2.95B
Cash Flow
Free Cash Flow	-254.40M	-168.16M	-153.27M	-377.75M	385.02M	946.88M
Operating Cash Flow	-225.48M	-39.76M	-49.43M	-260.76M	449.96M	964.21M
Investing Cash Flow	397.52M	201.03M	284.94M	329.59M	-305.47M	-772.39M
Financing Cash Flow	-135.11M	-180.81M	-219.11M	-124.26M	-51.77M	-171.56M

TTK Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1029.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TTKHLTCARE, the sentiment is Negative. The current price of 1029 is above the 20-day moving average (MA) of 888.25, above the 50-day MA of 941.34, and below the 200-day MA of 1119.67, indicating a bearish trend. The MACD of -32.40 indicates Positive momentum. The RSI at 19.15 is Positive, neither overbought nor oversold. The STOCH value of 19.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TTKHLTCARE.

TTK Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMRUTANJAN	72 Outperform	₹15.21B	24.83	―	0.68%	7.36%	19.31%
TTKHLTCARE	71 Outperform	₹11.57B	34.84	―	0.95%	6.98%	-17.11%
WINDLAS	71 Outperform	₹15.31B	27.93	―	0.71%	19.34%	9.32%
SMSPHARMA	70 Outperform	₹34.96B	29.96	―	0.13%	11.91%	36.92%
VIMTALABS	67 Neutral	₹18.57B	38.21	―	0.16%	17.05%	56.84%
BAJAJHCARE	52 Neutral	₹8.78B	20.91	―	0.24%	13.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

TTK Healthcare Limited Corporate Events

TTK Healthcare Seeks Shareholder Nod via E-Voting to Appoint New Independent Director

TTK Healthcare Limited has launched a postal ballot process to seek shareholder approval via special resolution for the appointment of Mr. V. Sundaresan as an Independent Director for a five-year term effective 22 December 2025. The company is conducting the process entirely through remote e-voting provided by CDSL, with notices emailed to eligible shareholders as of 19 December 2025 and voting scheduled between 26 December 2025 and 24 January 2026, underscoring its adherence to regulatory requirements and emphasis on transparent, digital-first corporate governance.

TTK Healthcare Board Appoints New Independent Director, Seeks Shareholder Nod via Postal Ballot

TTK Healthcare Limited’s board has approved the appointment of V. Sundaresan as an Additional Independent Director for a five-year term starting 22 December 2025, subject to shareholder approval via a special resolution. To secure this approval, the company will conduct a postal ballot through remote e-voting, appointing A K Jain & Associates as the scrutinizer to oversee the process, underscoring its emphasis on transparent governance and regulatory compliance under SEBI’s listing obligations.